NCT03217110

Brief Summary

The purpose of this study is to examine whether cerebellar stimulation can be used to improve cognitive deficits and mood in patients with schizophrenia, autism, bipolar disorder, Parkinson's disease, and major depression.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for not_applicable schizophrenia

Timeline
28mo left

Started Nov 2017

Longer than P75 for not_applicable schizophrenia

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress79%
Nov 2017Dec 2028

First Submitted

Initial submission to the registry

June 30, 2017

Completed
13 days until next milestone

First Posted

Study publicly available on registry

July 13, 2017

Completed
5 months until next milestone

Study Start

First participant enrolled

November 30, 2017

Completed
11 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2028

Last Updated

March 19, 2026

Status Verified

March 1, 2026

Enrollment Period

11 years

First QC Date

June 30, 2017

Last Update Submit

March 16, 2026

Conditions

Keywords

Cerebellum

Outcome Measures

Primary Outcomes (1)

  • Change in disease-specific symptom rating scale, one scale identified for each group (MADRS for bipolar group; PANSS for schizophrenia group; UPDRS in Parkinson's patient group).

    Change between pre- and post-assessments.

    During the 1 week of treatment, with follow up 1 week, 3 weeks, and 2 months post-stimulation.

Secondary Outcomes (15)

  • Change in brain rhythms

    During the 1 week of treatment, with follow up 1 week, 3 weeks, and 2 months post-stimulation.

  • Change in cognitive function

    During the 1 week of treatment, with follow up 1 week, 3 weeks, and 2 months post-stimulation.

  • Changes in functional MRI

    During the 1 week of treatment comparing pre- and post-stimulation scans.

  • Change in NIH Toolbox emotion battery

    During the 1 week of treatment, with follow up 1 week, 3 weeks, and 2 months post-stimulation.

  • Change in motor function

    During the 1 week of treatment, with follow up 1 week, 3 weeks, and 2 months post-stimulation.

  • +10 more secondary outcomes

Study Arms (4)

patient active rTMS

EXPERIMENTAL

Subjects will receive 5 days of 2x daily rTMS targeted over the cerebellum.

Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

patient sham rTMS

SHAM COMPARATOR

Subjects will receive 5 days of 2x daily sham stimulation of the cerebellum.

Device: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)

Control active rTMS

ACTIVE COMPARATOR
Device: Repetitive Transcranial Magnetic Stimulation (rTMS)

Control sham rTMS

SHAM COMPARATOR
Device: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)

Interventions

Subjects with neuropsychiatric diagnoses and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.

Also known as: Sham stimulation
Control sham rTMSpatient sham rTMS

Subjects with neuropsychiatric diagnoses and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.

Also known as: rTMS
Control active rTMSpatient active rTMS

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • A clinical diagnosis consistent with enrollment

You may not qualify if:

  • History of recurrent seizures or epilepsy
  • Any other neurological or psychiatric diagnosis outside the diagnosis for which the participant is enrolled.
  • Active substance use disorder in the past 6 months other than tobacco use disorder.
  • Inability to consent for study.
  • Pacemaker
  • Coronary Stent
  • Defibrillator
  • Neurostimulation
  • Claustrophobia
  • Uncontrolled high blood pressure
  • Atrial fibrillation
  • Significant heart disease
  • Hemodynamic instability
  • Kidney disease
  • Pregnant, trying to become pregnant, or breast feeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Iowa

Iowa City, Iowa, 52245, United States

RECRUITING

MeSH Terms

Conditions

SchizophreniaAutism Spectrum DisorderBipolar DisorderDepressionParkinson Disease

Interventions

Transcranial Magnetic Stimulation

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental DisordersChild Development Disorders, PervasiveNeurodevelopmental DisordersBipolar and Related DisordersMood DisordersBehavioral SymptomsBehaviorParkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Intervention Hierarchy (Ancestors)

Magnetic Field TherapyTherapeutics

Study Officials

  • Krystal L Parker, Ph.D

    Univeristy of Iowa

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Krystal L Parker, Ph.D

CONTACT

Benjamin Pace, M.S.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

June 30, 2017

First Posted

July 13, 2017

Study Start

November 30, 2017

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 1, 2028

Last Updated

March 19, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations